CHC

  • About Us
  • News
  • Coming Up
  • Resources
  • Contact Us
  • Search

Digitas: FDA Warning to Novartis Over Facebook Post Contains Upside

August 6, 2010

Read a detailed analysis of the DDMAC warning letter to Novartis about a Facebook posting that did not include appropriately posted warnings and contraindications.

Peter Pitts has more analysis canadian pharmacies online cialis in his blog at

how to remove genital warts

Please read, then come back here to comment.celebrex brand buy no prescription

Posted in General

Post navigation

Europe Beating U.S. Hands Down in Oncology
Associations React to NIH-Proposed Conflict of Interest Rules

Categories

  • CHC News
  • Courts/First Amendment
  • Data Privacy
  • Drug Pricing
  • DTC Advertising
  • General
  • Legislative
  • Off-label Promotion
  • Point of Care
  • Regulatory/FDA
  • Uncategorized
  • Washington Focus

Recent Posts

  • Could Burr’s New User Fee Bill Lead to Timely Passage of Legislation?
  • FDA Proposes Increased Consumer Access to Nonprescription Drugs, with Conditions
  • OPDP: Risk, Efficacy Claims for Cholesterol Drug in Doctor Promotion Are False/Misleading
  • HHS Formally Withdraws SUNSET Final Rule
  • OPDP Reorg, Outreach Efforts Designed to Improve Relationship with Industry

Tags

ad tax Advertising Coalition CDER CMS coalition for healthcare communication conflict of interest Congress COVID-19 data privacy DDMAC drug prices in DTC ads drug pricing DTC DTC advertising DTC advertising FDA FDA Commissioner FDA Draft Guidance FDA enforcement FDA social media free speech gifts to physicians HHS John Kamp Jon Bigelow kamp Kate Rawson legislation litigation marketing off-label off-label communication omission of risk OPDP OPDP enforcement PhRMA regulation Risk Information rx data Scott Gottlieb social media sunshine act Untitled Letter Warning Letter Wayne Pines
CHC

Smart Brief
© 2021 Coalition for Healthcare Communication. All rights reserved.